Waters Corporation recently introduced equity PREMIER Columns, a new family of premium sub-2-micron columns featuring MaxPeak High-Performance Surface (HPS) technology. The columns are for use with any brand of the UHPLC system and can measurably improve data quality by mitigating the loss of sample analytes due to analyte to-surface interactions. Designed for the analytical laboratory seeking to exercise greater control over their chromatographic separations, the columns improve sample throughput, assay-to-assay reproducibility, and overall confidence in analytical results.
“Analyte loss due to nonspecific adsorption is a significant problem that deserves more attention because of the cost of wasted effort and lost productivity. Most of the time, scientists don’t even know what they are missing. There are workarounds but they come with their own problems,” said Erin Chambers, VP, Chemistry, Waters Corporation.
Continue reading your story on the app
Continue reading your story in the magazine
We might need to redefine our approach to drug discovery and approval to be prepared for the future
Hitesh Windlass, MD,Windlas Biotech gives an overview of the changes bought by COVID-19 pandemic in the pharma industry, his organisation’s plans for future growth and more, in an interview with Lakshmpriya Nair
We help our customers create future-ready pharma manufacturing and biotech facilities
Sanjay Sudhakaran, VP, Digital Energy, Schneider Electric India expands on the value proposition of digital energy systems for the pharma sector, giving some examples of how companies achieved RoI on this investment, in an interaction with Viveka Roychowdhury
Virtual clinical trials would have a tremendous advantage in expanding the reach of clinical trials
Suneela Thatte, VP and Head - R&D Solutions India, IQVIA speaks on the challenges faced by CROs due to the pandemic, the subsequent learnings in clinical research/trials, emerging trends in this arena and more, in an interaction with Viveka Roychowdhury
Waters Corporation appoints Pearl S Huang to Board of Directors
She has significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as in drug discovery and the development of clinical trials
Fighting counterfeiting requires a long-term battle and we need to start somewhere
Globally, incidents of fake, counterfeit pharma products are on the rise and recent cyber attacks on some pharma companies involved in the development of COVID-19 vaccines are raising further alarm. Nakul Pasricha, President, Authentication Solution Providers’ Association (ASPA) talks about the need for a phygital approach to secure supply chain integrity and facilitate easy identification of genuine COVID-19 vaccines, with Usha Sharma
FDI in brownfield pharma projects - Critical analysis
Arvind Sharma, Partner, Shardul Amarchand Mangaldas & Co informs that the extant regulatory regime for FDI in brownfield projects follows a balanced approach as it safeguards supplies for domestic consumption and ensures foreign investments as well as technological advancement for the pharma sector
Effective effluent management: Key to tackle AMR
Dr Jyoti Joshi, Head-South Asia,The Center for Disease Dynamics, Economics & Policy (CDDEP); Adjunct Professor,Amity Institute of Public Health emphasises that the government and the pharma industry need to establish strategic partnerships to address the issue of growing AMR due to pharma plant effluents
CIMS Medica organises Business Excellence Awards 2020
The award ceremony was held at the The Leela Palace Hotel, New Delhi to honour companies who contributed to the growth and development of the healthcare and pharma industry
BLUEPRINT FOR PROGRESS
Experts and veterans examine and explore strategies for India Pharma Inc to implement the lessons learnt from the COVID-19 pandemic as we enter a new year and a new decade
Reverse Brain Drain: Accelerated By Covid-19
Ankit Goyal, Healthcare and Lifesciences Leader India, Heidrick & Struggles finds that leadership hiring is attracting ‘returnee Indians’ in healthcare companies due to growing opportunities in India, and more recently, the impact of the pandemic
